On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
In the milk of 30 genetically modified goats on GTC Biotherapeutics's farm in Charlton, Mass., is a drug that can literally make your blood flow--the human protein antithrombin, which inhibits clotting. In a dramatic reversal, after European reg-ulators rejected this drug (called ATryn), they now look ready to approve it later this year. The ruling would make ATryn the first human protein made by a transgenic animal for commercial production.
Perhaps more important, the judgment in favor of the goats paves the way for more drug-making transgenic farm animals. Origen Therapeutics in Burlingame, Calif., has developed a versatile, cost-effective method for genetically transforming chickens--one that is on par with creating transgenic mice, now common in the lab. In principle, the birds could produce a variety of different proteins in their eggs, including drugs.
Subscribe to Support Independent Journalism
Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.
When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.
Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber
